Dufies et al. investigated the effects of various CXCR1/2 blocking agents in ectopic models of RCC and identified compound C29 to inhibit primary tumor cell growth and ELR+CXCL-mediated proliferation and migration of endothelial cells [323]. This evidence concerns the gene CXCR1 and neoplasm.